|Bid||52.75 x 100|
|Ask||0.00 x 0|
|Day's Range||55.96 - 56.18|
|52 Week Range||45.43 - 56.75|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.11%|
There have been few changes since we first began issuing Morningstar Analyst Ratings for ETFs one year ago, but we've ramped up coverage dramatically.
With international equities outpacing U.S. stocks and luring U.S. investors in the process, investors would do well to remember one of the largest ex-US exchange traded funds: The Vanguard Total International ...
In 1H17, Novartis's (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.
GlaxoSmithKline (GSK) added new products and improved the supply chain for consumer healthcare products in the last few years.
In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.
Vanguard International Dividend Appreciation focuses on profitable firms that have consistently increased their dividend payments.
CP hauled slightly more than 30,000 railcars in the 30th week compared with over 29,000 railcars in the 30th week last year.
First Ascent Asset Management is a newcomer in the ETF strategist space, building two series of portfolios for advisors: one using only ETFs, the other combining ETFs with actively managed mutual funds.
Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.
In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.
A foundation I work with asked me to compare its performance with that of other foundations using the most recent data available. The news was quite good. This relatively small foundation (“Foundation X”) managed to beat the return averages for all size foundations and even the top 10 percentile of performance of all foundations. Yet it is the story of how it achieved this that is most compelling, as any individual or foundation can do the same.
AstraZeneca's (AZN) Respiratory segment is one its key growth platforms. The segment reported nearly flat revenue of $1.2 billion at constant exchange rates in 1Q17.